Takara Bio Inc.

Takara Bio Inc. operates in reagents, equipment, contract services, and genetic medicine across Japan, China, the rest of Asia, the United States, Europe, and internationally. It sells reagents and instruments for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. The company also offers contract services for regenerative medicine products and for gene analysis and testing. In addition, it is involved in commercializing its proprietary platform technology for biologics development, developing and selling ancillary materials such as RetroNectin for gene therapy manufacturing, seeking marketing authorization for the NY-ESO-1 siTCR gene therapy product, and developing JAK/STAT technology for CAR gene therapy and the brain-tropic adeno-associated virus vector CereAAV. Products and services are provided through sales agents or directly to customers. Incorporated in 2002 and headquartered in Kusatsu, Japan, Takara Bio Inc. is a subsidiary of Takara Holdings Inc.